Summary
- High value cancer therapeutic product pipeline going into phase 1/2a studies in solid tumors;
- Revenue generating diagnostics division with multiple licenses and regular royalty expected from late 2014;
- Revenue generating consumer health division with strong growth from emerging markets in 2014 onwards;
- High value assets underpinned by strong revenue growth.
To view Presentation please download PDF below:
